MENTOR · Metabolic control of cell growth by mTOR in health and disease: a multi-disciplinary training
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2025-01-01 → 2028-12-31
- Финансиране от ЕС
- 3 953 988 €
- Участници
- 26
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите.
Накратко на български
Пътят на протеина mTOR контролира растежа на клетките и метаболизма, като неговите нарушения водят до заболявания като поликистоза на бъбреците. Разбирането на тези механизми помага за разработването на подходящи лекарства и прилагането на персонализирана медицина за милиони хора.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
MENTOR is a multi-disciplinary training network which focuses on the mTOR pathway, a central mechanistic hub that integrates nutritional cues and controls cell growth and metabolism. Aberrant activation of mTOR underlies monogenic diseases with broad spectrum of pathological manifestations, including tissue overgrowth, polycystic kidneys and neuropsychiatric disorders affecting around two million of people worldwide. To avoid the medical errancy of patients in different clinical departments and surgical mutilations, approaches of personalized medicine depending on the genetic landscape need to be implemented, taking advantage of suitable pharmacological products. The overall goal of the MENTOR research program is to: delineate molecular mechanisms of fundamental and aberrant mTOR functions, preclinically decipher the pathophysiology of mTOR, develop a novel arsenal of drugs to selectively target the pathway and provide proof-of-concept support for such interventions. This ambition can only be achieved by the multidisciplinary research program that MENTOR has conceived, through the training of a new generation of scientists at Graduate Schools of biology, pharmacy, chemistry or medicine that will become the leaders of mTOR research in both public and private sectors. MENTOR will establish a collaborative and efficient network from academia to industry, involving patient associations and clinicians with impact on scientific community and society.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITE PARIS CITE · ParisКоординаторФранция
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS · ParisФранция
- BIOSOLVEIT GMBH · Sankt AugustinГермания
- Cell Signaling Technology, Inc. · DanversСъединени щати
- EBERHARD KARLS UNIVERSITAET TUEBINGEN · TuebingenГермания
- European Tuberous Sclerosis Complex Association (e-tsc) · WiesbadenГермания
- FONDAZIONE TELETHON ETS · ROMAИталия
- FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III · MadridИспания
- IDRYMA TECHNOLOGIAS KAI EREVNAS · IRAKLEIOГърция
- INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE · ParisФранция
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisФранция
- KATHOLIEKE UNIVERSITEIT LEUVEN · LeuvenБелгия
- MIEDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMORKOWEJ W WARSZAWIE · WarszawaПолша
- MIEDZYNARODOWY INSTYTUT MECHANIZMOW I MASZYN MOLEKULARNYCH POLSKIEJ AKADEMII NAUK · WARSZAWAПолша
- MIMETAS BV · LeidenНидерландия
- PANEPISTIMIO IOANNINON · IOANNINAГърция
- PD-VALUE BV · HoutenНидерландия
- SORBONNE UNIVERSITE · ParisФранция
- The Myrovlytis Trust · LONDONОбединеното кралство
- Topadur Pharma AG · SchlierenШвейцария
- UNIVERSIDAD AUTONOMA DE MADRID · MadridИспания
- UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II · NapoliИталия
- UNIVERSITAETSKLINIKUM ESSEN · EssenГермания
- UNIVERSITAIR MEDISCH CENTRUM UTRECHT · UtrechtНидерландия
- UNIVERSITAT BASEL · BaselШвейцария
- UNIVERSITE DE FRIBOURG · FribourgШвейцария
Връзки
Данни: CORDIS, © Европейски съюз